New Balance Between Scientific & Commercial Practicalities for Diverse Clinical Trials
Despite regulatory ambiguity, most sponsors remain committed to diversity in clinical trials as a scientific and operational imperative.
Already a DIA Member? Sign in. Not a member? Join.
Sign in
Not a Member?
The Industry Doesn't Wait.
Neither Should You
Early bird pricing is in effect. Secure your spot now.
Register for DIA 2027
Explore Hot Topics
FDA Tightens Expectations for Biosimilar Promotion
Explore 2025 US FDA Q&A Guidance on rendering information about reference and biosimilar products in promotional labeling and advertisements.
Regulatory Affairs Training Course
Virtual training course explains FDA regulations and expectations for content, submission, and review of INDs and NDAs.
